{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:17Z","timestamp":1792806137462,"version":"4.5.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Poliomyelitis has been a significant global health challenge for centuries. Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, remarkable progress has been achieved, with wild poliovirus (WPV) cases reduced by over 99%. However, challenges persist, including endemic transmission in conflict zones, the emergence of vaccine-derived polioviruses (VDPVs), and the complex logistics of vaccine production and distribution. This review synthesized the latest advancements in poliovirus vaccine development, production, and global deployment. Specific topics include the historical milestones of inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV), innovations in next-generation vaccines such as novel OPV (nOPV2), intradermal IPV (IIPV), virus-like particle (VLP) vaccines, and mRNA vaccines, as well as critical considerations in manufacturing, quality control, and regulatory compliance. We also examined global strategies for vaccination campaigns, cold chain management, and eradication-endgame planning, alongside emerging challenges like VDPVs outbreaks, funding constraints, and geopolitical barriers. The significance of sustained global cooperation, equitable resource allocation, and technological advancement are essential to achieving a polio-free world, with the integration of scientific innovation with public health strategies. The lessons and insights presented herein inform polio eradication efforts, providing a blueprint for future disease eradication initiatives. The importance of resilience, adaptability, and community engagement was also emphasized for global health governance.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1611028","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:37:49Z","timestamp":1752644269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances and challenges in poliomyelitis vaccines: a comprehensive review of development, production, and global deployment"],"prefix":"10.3389","volume":"13","author":[{"given":"Jia","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1941874414533352","article-title":"Poliomyelitis: historical facts, epidemiology, and current challenges in eradication","volume":"4","author":"Mehndiratta","year":"2014","journal-title":"Neurohospitalist"},{"key":"ref2","first-page":"S61","article-title":"Global polio eradication, the journey so far","volume":"53","author":"Thacker","year":"2016","journal-title":"Indian Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e107697","DOI":"10.1371\/journal.pone.0107697","article-title":"Molecular characterization and phylogenetic relationship of wild type 1 poliovirus strains circulating across Pakistan and Afghanistan bordering areas during 2010-2012","volume":"9","author":"Shaukat","year":"2014","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"Cd011260","DOI":"10.1002\/14651858.CD011260.pub2","article-title":"Sequential inactivated (Ipv) and live oral (Opv) poliovirus vaccines for preventing poliomyelitis","volume":"12","author":"Ciapponi","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","article-title":"Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa","volume":"22","author":"Cooper","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.15585\/mmwr.mm7313a1","article-title":"Surveillance to track Progress toward polio eradication - worldwide, 2022-2023","volume":"73","author":"Kishore","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.coviro.2012.02.006","article-title":"Reaching the last one per cent: progress and challenges in global polio eradication","volume":"2","author":"Kew","year":"2012","journal-title":"Curr Opin Virol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.4161\/hv.32253","article-title":"Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system","volume":"10","author":"White","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","article-title":"Expert review on poliovirus immunity and transmission","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1093\/clinids\/6.Supplement_2.S352","article-title":"Modes of action of poliovirus vaccines and relation to resulting immunity","volume":"6","author":"Fox","year":"1984","journal-title":"Rev Infect Dis"},{"key":"ref11","volume-title":"Polio vaccine","author":"O'grady","year":"2025"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1093\/cid\/ciy634","article-title":"Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses","volume":"67","author":"Bhaumik","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41577-023-00897-3","article-title":"Memory B cells","volume":"24","author":"Inoue","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.procbio.2019.03.010","article-title":"Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors","volume":"81","author":"Jiang","year":"2019","journal-title":"Process Biochem"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1016\/j.vaccine.2014.02.022","article-title":"Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods","volume":"32","author":"Thomassen","year":"2014","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.vaccine.2012.10.070","article-title":"Per.C6((R)) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine","volume":"31","author":"Sanders","year":"2013","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1016\/j.vaccine.2015.10.091","article-title":"Production of high titer attenuated poliovirus strains on the serum-free per.C6((R)) cell culture platform for the generation of safe and affordable next generation Ipv","volume":"33","author":"Sanders","year":"2015","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.1016\/j.vaccine.2018.09.068","article-title":"An inactivated poliovirus vaccine using Sabin strains produced on the serum-free per.C6(R) cell culture platform is immunogenic and safe in a non-human primate model","volume":"36","author":"Bockstal","year":"2018","journal-title":"Vaccine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4155\/ppa.12.70","article-title":"Innovative Ipv from attenuated Sabin poliovirus or newly designed alternative seed strains","volume":"1","author":"Hamidi","year":"2012","journal-title":"Pharm Pat Anal"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/bit.27486","article-title":"Formulation and production of a blood-free and chemically defined virus production media for Vero cells","volume":"117","author":"Alfano","year":"2020","journal-title":"Biotechnol Bioeng"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7774\/cevr.2020.9.1.48","article-title":"Suspension culture of Vero cells for the production of adenovirus type 5","volume":"9","author":"Lee","year":"2020","journal-title":"Clin Exp Vaccine Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8615","DOI":"10.1016\/j.vaccine.2011.09.015","article-title":"Viral interference induced by live attenuated virus vaccine (Opv) can prevent otitis media","volume":"29","author":"Seppala","year":"2011","journal-title":"Vaccine"},{"key":"ref24","author":"Runo","year":"2025","journal-title":"Engineering local Kenyan Irish potato varieties as carriers for edible cholera vaccines"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101298","article-title":"An algae-made Rbd from Sars-CoV-2 is immunogenic in mice","volume":"15","author":"Govea-Alonso","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(23)02844-1","article-title":"Safety of the novel oral poliovirus vaccine type 2 (nopv2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nopv2 in infants in the Gambia: a phase 3, double-blind, randomised controlled trial","volume":"403","author":"Ochoge","year":"2024","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/infdis\/jiad222","article-title":"Impact of supplementary immunization activities using novel Oral polio vaccine type 2 during a large outbreak of circulating vaccine-derived poliovirus in Nigeria","volume":"229","author":"Voorman","year":"2024","journal-title":"J Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"757375","DOI":"10.3389\/fmicb.2021.757375","article-title":"Dose-sparing intradermal DtaP-sipv immunization with a hollow microneedle leads to superior immune responses","volume":"12","author":"Zuo","year":"2021","journal-title":"Front Microbiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1093\/infdis\/jix038","article-title":"Intradermal Administration of Fractional Doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization","volume":"216","author":"Okayasu","year":"2017","journal-title":"J Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (Ipv) and intradermal fractional dose Ipv administered by a microneedle device: a randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41467-025-56118-z","article-title":"Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines","volume":"16","author":"Sherry","year":"2025","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e0430022","DOI":"10.1128\/spectrum.04300-22","article-title":"Protease-independent production of poliovirus virus-like particles in Pichia pastoris: implications for efficient vaccine development and insights into capsid assembly","volume":"11","author":"Sherry","year":"2023","journal-title":"Microbiol Spectr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e0169533","DOI":"10.1371\/journal.pone.0169533","article-title":"Chimeric L2-based virus-like particle (Vlp) vaccines targeting cutaneous human papillomaviruses (Hpv)","volume":"12","author":"Huber","year":"2017","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12091077","article-title":"Vaccine potency and structure of yeast-produced polio type 2 stabilized virus-like particles","volume":"12","author":"Hong","year":"2024","journal-title":"Vaccines"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00838-19","article-title":"Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris","volume":"5","author":"Sherry","year":"2020","journal-title":"mSphere"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/erv.13.10","article-title":"Virus-like particle-based vaccines against hepatitis C virus infection","volume":"12","author":"Bellier","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/vim.2024.0047","article-title":"The potential of mrna vaccines to fight against viruses","volume":"37","author":"Wang","year":"2024","journal-title":"Viral Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41541-025-01157-2","article-title":"Characterization of a suspension Vero cell line for viral vaccine production","volume":"10","author":"Bourigault","year":"2025","journal-title":"Npj Vaccines"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"840077","DOI":"10.3389\/fimmu.2022.840077","article-title":"Electron-beam inactivation of human rotavirus (Hrv) for the production of neutralizing egg yolk antibodies","volume":"13","author":"Skrobarczyk","year":"2022","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jviromet.2013.01.016","article-title":"Complete and repeatable inactivation of Hiv-1 viral particles in suspension using a photo-labeled non-nucleoside reverse transcriptase inhibitor","volume":"189","author":"Marin-Muller","year":"2013","journal-title":"J Virol Methods"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e1700718","DOI":"10.1002\/biot.201700718","article-title":"Continuous in-line virus inactivation for next generation bioprocessing","volume":"14","author":"Gillespie","year":"2019","journal-title":"Biotechnol J"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0042-6822(92)90565-7","article-title":"Correlation of Rna secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture","volume":"189","author":"Macadam","year":"1992","journal-title":"Virology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1128\/JVI.00370-06","article-title":"Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication","volume":"80","author":"Macadam","year":"2006","journal-title":"J Virol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41586-023-06212-3","article-title":"Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3","volume":"619","author":"Yeh","year":"2023","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e1012415","DOI":"10.1371\/journal.ppat.1012415","article-title":"Adaptive truncation of the S gene in Ibv during chicken embryo passaging plays a crucial role in its attenuation","volume":"20","author":"Liang","year":"2024","journal-title":"PLoS Pathog"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/risa.13590","article-title":"Expected implications of globally coordinated cessation of serotype 3 Oral poliovirus vaccine (Opv) before serotype 1 Opv","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1016\/j.vaccine.2019.09.082","article-title":"Pharmacovigilance capacity strengthening for who prequalification: the case of the trivalent influenza vaccine manufactured by Instituto Butantan","volume":"37","author":"Koike","year":"2019","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13020116","article-title":"Establishment of a poliovirus containment program and containment certification process for poliovirus-essential facilities, United States 2017-2022","volume":"13","author":"Ottendorfer","year":"2024","journal-title":"Pathogens"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.healthpol.2021.03.013","article-title":"Scaling up the global Covid-19 vaccination program: production, allocation, and distribution with an emphasis on equity","volume":"95","author":"Louden","year":"2022","journal-title":"Yale J Biol Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14760584.2024.2361060","article-title":"Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (Sias)","volume":"23","author":"Thompson","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2471\/BLT.11.092494","article-title":"Supplementary polio immunization activities and prior use of routine immunization services in non-polio-endemic sub-Saharan Africa","volume":"90","author":"Helleringer","year":"2012","journal-title":"Bull World Health Organ"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/infdis\/jiv589","article-title":"Revised household-based microplanning in polio supplemental immunization activities in Kano state, Nigeria. 2013-2014","volume":"213","author":"Gali","year":"2016","journal-title":"J Infect Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.4103\/1119-3077.144406","article-title":"Experiences from polio supplementary immunization activities in Anambra state, Nigeria","volume":"17","author":"Onyeka","year":"2014","journal-title":"Niger J Clin Pract"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"21501327211029800","DOI":"10.1177\/21501327211029800","article-title":"Polio supplementary immunization activities during Covid-19 pandemic: experience from Penampang District, Sabah, Malaysia","volume":"12","author":"Jiee","year":"2021","journal-title":"J Prim Care Community Health"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12887-024-05284-y","article-title":"Health workers' knowledge and practices toward vaccine cold chain management and its associated factors in a resource-limited setting of Sheger, Oromia, Ethiopia: a multicenter cross-sectional study","volume":"24","author":"Geneti","year":"2024","journal-title":"BMC Pediatr"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12916-017-0937-y","article-title":"The risk of type 2 oral polio vaccine use in post-cessation outbreak response","volume":"15","author":"Mccarthy","year":"2017","journal-title":"BMC Med"},{"key":"ref61","year":""},{"key":"ref62","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.vaccine.2012.06.020","article-title":"Oral and inactivated poliovirus vaccines in the newborn: a review","volume":"31","author":"Mateen","year":"2013","journal-title":"Vaccine"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121323","article-title":"Polio epidemiology: strategies and challenges for polio eradication post the COVID-19 pandemic","volume":"12","author":"Bricks","year":"2024","journal-title":"Vaccines"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12879-015-0745-y","article-title":"Cross-border collaboration between China and Myanmar for emergency response to imported vaccine derived poliovirus case","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref66","article-title":"Analysis of poliomyelitis eradication and recommendations for immunization strategies","author":"Huang Zhuoying","year":"2020","journal-title":"J Microbes Infections"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1080\/21645515.2018.1489188","article-title":"Immunogenicity of sequential inactivated and oral poliovirus vaccines (Opv) versus inactivated poliovirus vaccine (Ipv) alone in healthy infants: a systematic review and meta-analysis","volume":"14","author":"Tang","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. Efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O'ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"913","DOI":"10.15585\/mmwr.mm6433a5","article-title":"World Health Organization guidelines for containment of poliovirus following type-specific polio eradication - worldwide, 2015","volume":"64","author":"Previsani","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.15585\/mmwr.mm6838a3","article-title":"Progress toward poliovirus containment implementation - worldwide, 2018-2019","volume":"68","author":"Moffett","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref72","first-page":"881","article-title":"Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status","volume":"137","author":"John","year":"2013","journal-title":"Indian J Med Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4269\/ajtmh.18-0931","article-title":"Involvement of civil Society in India's polio eradication program: lessons learned","volume":"101","author":"Solomon","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"ref74","first-page":"S7","article-title":"The estimated health and economic benefits of three decades of polio elimination efforts in India","volume":"53","author":"Nandi","year":"2016","journal-title":"Indian Pediatr"},{"key":"ref75","first-page":"S50","article-title":"Role of social mobilization (network) in polio eradication in India","volume":"53","author":"Siddique","year":"2016","journal-title":"Indian Pediatr"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4161\/hv.20089","article-title":"Inactivated polio vaccine: time to introduce it in India's national immunization schedule","volume":"8","author":"Verma","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2237390","DOI":"10.1080\/21645515.2023.2237390","article-title":"Polio vaccination activities in conflict-affected areas","volume":"19","author":"Mbaeyi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1093\/infdis\/jix175","article-title":"Approaches to vaccination among populations in areas of conflict","volume":"216","author":"Nnadi","year":"2017","journal-title":"J Infect Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"227","DOI":"10.15585\/mmwr.mm6608a6","article-title":"Response to a large polio outbreak in a setting of conflict - Middle East, 2013-2015","volume":"66","author":"Mbaeyi","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2214-109X(17)30184-5","article-title":"Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial","volume":"5","author":"Habib","year":"2017","journal-title":"Lancet Glob Health"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","volume":"41","author":"Kalkowska","year":"","journal-title":"Vaccine"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/01634372.2021.1879339","article-title":"\"advocating every single day\" so as not to be forgotten: factors supporting resiliency in adult day service centers amidst Covid-19-related closures","volume":"64","author":"Sadarangani","year":"2021","journal-title":"J Gerontol Soc Work"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.1016\/j.vaccine.2021.04.026","article-title":"The impact of disruptions caused by the Covid-19 pandemic on global polio eradication","volume":"41","author":"Kalkowska","year":"","journal-title":"Vaccine"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20021618","article-title":"Geopolitical risk evolution and obstacle factors of countries along the belt and road and its types classification","volume":"20","author":"Hu","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6441a2","article-title":"Progress toward poliomyelitis eradication--Afghanistan, January 2014\u2013august 2015","volume":"64","author":"Mbaeyi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/0020731417722888","article-title":"How drone strikes and a fake vaccination program have inhibited polio eradication in Pakistan: an analysis of National Level Data","volume":"47","author":"Kennedy","year":"2017","journal-title":"Int J Health Serv"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12889-019-6393-1","article-title":"Achieving the end game: employing \"vaccine diplomacy\" to eradicate polio in Pakistan","volume":"19","author":"Shakeel","year":"2019","journal-title":"BMC Public Health"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1186\/s12889-020-09235-x","article-title":"Conflict, community, and collaboration: shared implementation barriers and strategies in two polio endemic countries","volume":"20","author":"Owoaje","year":"2020","journal-title":"BMC Public Health"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/risa.13194","article-title":"Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan","volume":"39","author":"Duintjer Tebbens","year":"2019","journal-title":"Risk Anal"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"788","DOI":"10.15585\/mmwr.mm7336a2","article-title":"Progress toward poliomyelitis eradication - Pakistan, January 2023-June 2024","volume":"73","author":"Mbaeyi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.15585\/mmwr.mm695152a4","article-title":"Impact of Covid-19 pandemic on global poliovirus surveillance","volume":"69","author":"Zomahoun","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13346-018-00608-9","article-title":"Development of a thermostable microneedle patch for polio vaccination","volume":"9","author":"Kolluru","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"e1900635","DOI":"10.1002\/adhm.201900635","article-title":"Upconversion nanoparticle powered microneedle patches for transdermal delivery of siRNA","volume":"9","author":"Wang","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/pbi.13060","article-title":"Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes","volume":"17","author":"Daniell","year":"2019","journal-title":"Plant Biotechnol J"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1038\/s41467-023-41052-9","article-title":"A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes","volume":"14","author":"Charnesky","year":"2023","journal-title":"Nat Commun"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1016\/j.vaccine.2023.08.036","article-title":"Development and characterization of a plant-derived norovirus-like particle vaccine","volume":"41","author":"Shapiro","year":"2023","journal-title":"Vaccine"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41467-017-00090-w","article-title":"Plant-made polio type 3 stabilized Vlps-a candidate synthetic polio vaccine","volume":"8","author":"Marsian","year":"2017","journal-title":"Nat Commun"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/a-2181-2886","article-title":"Establishment of the Daucus carota Smc-1 cell suspension line for poliovirus vaccine development","volume":"90","author":"Morales-Aguilar","year":"2024","journal-title":"Planta Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"55","DOI":"10.29063\/ajrh2016\/v20i3.10","article-title":"Achieving health Sdg 3 in Africa through Ngo capacity building - insights from the gates Foundation Investment in Partnership in advocacy for child and family health (PacfaH) project","volume":"20","author":"Walker","year":"2016","journal-title":"Afr J Reprod Health"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"e14664","DOI":"10.2196\/14664","article-title":"A collaborative initiative to strengthen sustainable public health capacity for polio eradication and routine immunization activities in the eastern Mediterranean region","volume":"5","author":"Al Gunaid","year":"2019","journal-title":"JMIR Public Health Surveill"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1128\/AEM.03575-14","article-title":"Environmental surveillance of poliovirus in sewage water around the introduction period for inactivated polio vaccine in Japan","volume":"81","author":"Nakamura","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"ref102","first-page":"501","article-title":"The global polio eradication initiative stop transmission of polio (stop) program - 1999-2013","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1611028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:37:52Z","timestamp":1752644272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1611028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":102,"alternative-id":["10.3389\/fpubh.2025.1611028"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1611028","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1611028"}}